Showing 761-780 of 8875 for: Cochrane Systematic Reviews Back
- Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks
Cochrane Systematic Reviews, 8-May-2008
People with nonrheumatic atrial fibrillation who have had a transient ischemic attack or minor ischemic stroke are at risk of recurrent stroke.
- Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
Cochrane Systematic Reviews, 6-Mar-2011
Non-valvular atrial fibrillation (AF) carries an increased risk of stroke. Antiplatelet therapy (APT) is proven effective for stroke prevention in most patients at high-risk for vascular events, but its value for primary stroke prevention in patients with
- Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm
Cochrane Systematic Reviews, 15-Sep-2016
Morbidity in patients with chronic heart failure is high, and this predisposes them to thrombotic complications, including stroke and thromboembolism, which in turn contribute to high mortality. Oral anticoagulants (e.g. warfarin) and antiplatelet agents
- Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams
Cochrane Systematic Reviews, 11-Feb-2015
Several beta-lactams are recommended as single agents for the treatment of febrile neutropenia.
- Antipsychotic combinations for schizophrenia
Cochrane Systematic Reviews, 28-Jun-2017
Many people with schizophrenia do not achieve a satisfactory treatment response with their initial antipsychotic drug treatment. Sometimes a second antipsychotic, in combination with the first, is used in these situations.
- Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
Cochrane Systematic Reviews, 24-Nov-2022
Antipsychotic drugs are the mainstay treatment for schizophrenia, yet they are associated with diverse and potentially dose-related side effects which can reduce quality of life. For this reason, the lowest possible doses of antipsychotics are generally r
- Antipsychotic drug treatment for elderly people with late‐onset schizophrenia
Cochrane Systematic Reviews, 15-Feb-2012
Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schi
- Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum
Cochrane Systematic Reviews, 20-Oct-2008
Antipsychotics are commonly prescribed for women suffering psychotic illnesses during pregnancy and the postpartum period. The potential adverse consequences of these different options are multiple and complex, impacting on the foetus, neonate, infant and
- Antipsychotic medication for challenging behaviour in people with learning disability
Cochrane Systematic Reviews, 11-Nov-2008
The term 'challenging behaviour', in the absence of psychiatric disorder, encompasses a wide range of behaviours that may be harmful to people or property, may be difficult to manage and may limit access to community facilities. Antipsychotic medications
- Antipsychotic medication for childhood‐onset schizophrenia
Cochrane Systematic Reviews, 18-Jul-2007
Childhood-onset schizophrenia is schizophrenia with onset prior to the age of 13 years. Although it is rare, people who suffer from schizophrenia at an early age appear to have a clinically severe form of the illness with poor long-term prognosis. Antipsy
- Antipsychotic medication for early episode schizophrenia
Cochrane Systematic Reviews, 16-Feb-2017
Long-term treatment with antipsychotic medications in early episode schizophrenia spectrum disorders is common, but both short and long-term effects on the illness are unclear. There have been numerous suggestions that people with early episodes of schizo
- Antipsychotic medication for elderly people with schizophrenia
Cochrane Systematic Reviews, 25-Jan-2006
A large and growing number of older people across the world suffer from schizophrenia. Recommendations for their treatment are largely based on data extrapolated from studies of the use of antipsychotic medications in younger populations. In addition most
- Antipsychotic medication versus placebo for people with both schizophrenia and learning disability
Cochrane Systematic Reviews, 17-Dec-2012
Antipsychotic medication is the standard treatment for people with learning disability and schizophrenia.
- Antipsychotic medications for cocaine dependence
Cochrane Systematic Reviews, 19-Mar-2016
Cocaine dependence is a public health problem characterised by recidivism and a host of medical and psychosocial complications. Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists.
- Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
Cochrane Systematic Reviews, 30-Aug-2022
In clinical practice, different antipsychotics can be combined in the treatment of people with schizophrenia (polypharmacy). This strategy can aim at increasing efficacy, but might also increase the adverse effects due to drug–drug interactions. Reducing
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
Cochrane Systematic Reviews, 6-Feb-2018
Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such
- Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
Cochrane Systematic Reviews, 24-Jan-2013
Weight gain is common for people with schizophrenia and this has serious implications for a patient's health and well being. Switching strategies have been recommended as a management option.
- Antipsychotics for acute and chronic pain in adults
Cochrane Systematic Reviews, 29-Aug-2013
This is an updated version of the original Cochrane review published in Issue 4, 2008. The role of antipsychotics as adjuvant analgesics is a subject of longstanding controversy. Neuroleptanalgesia (that is a state of quiescence, altered awareness, and an
- Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia
Cochrane Systematic Reviews, 17-Dec-2021
Typical and atypical antipsychotics are widely used to treat agitation and psychosis in dementia. However, whether or not they are beneficial is uncertain. Some trials have yielded negative results and effectiveness may be outweighed by harms.
- Antipsychotics for fibromyalgia in adults
Cochrane Systematic Reviews, 2-Jun-2016
This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue. It affects